|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.001500 EUR | -.--% |
|
-.--% | -25.00% |
| 07-23 | WINNERS & LOSERS: capAI gains exclusive licence for Ageotype platform | AN |
| 07-21 | WINNERS & LOSERS: Harvest Minerals surges on Brazil portfolio takeover | AN |
| Market Cap | 3.78M 5.09M 4.43M 4.12M 7.15M 486M 7.26M 48.58M 19.07M 242M 19.13M 18.71M 812M | P/E 2024 |
-0.13x | P/E 2025 | -5.88x |
|---|---|---|---|---|---|
| Enterprise Value | 3.69M 4.96M 4.31M 4.02M 6.96M 474M 7.07M 47.33M 18.58M 236M 18.64M 18.23M 791M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
94.63% | Yield 2024 * |
-
| Yield 2025 | - |
| 23/05/25 | Nuformix : Prospectus | PU |
| 05/10/23 | Nuformix to fund its unlicensed programs with NXP001 windfall | AQ |
| 20/12/22 | Nuformix hoping to "initiate discussions with major pharma" in 2023 | AQ |
| 20/12/22 | Nuformix hoping to 'initiate discussions with major pharma' in 2023 | EQ |
| 18/02/20 | Nuformix : Appointment of Dr Karl Keegan | PU |
| 1 month | +200.00% | ||
| 3 months | +200.00% | ||
| 6 months | +50.00% | ||
| Current year | -25.00% |
| 1 week | 0 |  | 0 |
| 1 month | 0 | | 0 |
| 3 years | 0 | | 0 |
| 5 years | 0 | | 0.02 |
| Manager | Title | Age | Since |
|---|---|---|---|
Shaun Zulafqar
SEC | Corporate Secretary | - | 29/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Daniel Gooding
CHM | Chairman | 53 | 05/02/2020 |
Julian Gilbert
CHM | Chairman | 65 | 28/07/2022 |
| Director/Board Member | 61 | 02/12/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | +200.00% | -25.00% | 5.09M | |
| -0.53% | -3.95% | +55.23% | +152.74% | 1,024B | |
| +0.21% | -2.68% | +55.61% | +53.02% | 618B | |
| -2.51% | -3.25% | +32.76% | +67.76% | 443B | |
| +0.06% | -0.42% | +37.53% | +30.67% | 349B | |
| -0.14% | -0.24% | +34.41% | +39.01% | 297B | |
| -0.69% | -0.30% | +11.55% | +12.93% | 264B | |
| -7.37% | -4.40% | -2.54% | -43.87% | 209B | |
| -0.64% | +2.43% | +30.52% | +64.49% | 208B | |
| -0.82% | +0.70% | +15.96% | +71.01% | 162B | |
| Average | -1.38% | -1.20% | +47.10% | +42.28% | 397.08B | |
| Weighted average by Cap. | -0.99% | -1.93% | +39.24% | +72.95% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -3.64M -4.9M -4.26M -3.97M -6.88M -468M -6.98M -46.75M -18.35M -233M -18.41M -18M -781M | -653K -878K -764K -711K -1.23M -83.86M -1.25M -8.38M -3.29M -41.75M -3.3M -3.23M -140M |
| Net Debt | -20.21K -27.2K -23.65K -22.01K -38.16K -2.6M -38.76K -259K -102K -1.29M -102K -99.93K -4.34M | -97.55K -131K -114K -106K -184K -12.54M -187K -1.25M -492K -6.24M -493K -482K -20.93M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change |
|---|---|---|
| 31/07/26 | €0.001500 | -.--% |
| 30/07/26 | €0.001500 | -.--% |
| 29/07/26 | €0.001500 | -.--% |
| 28/07/26 | €0.001500 | -.--% |
| 27/07/26 | €0.001500 | -.--% |
- Stock Market
- Stocks
- LVRT Stock
- 1RT Stock
Select your edition
All financial news and data tailored to specific country editions
